• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

吡唑并[4,3-c]吡啶磺酰胺类碳酸酐酶抑制剂:合成、生物学及计算机模拟研究

Pyrazolo[4,3-c]pyridine Sulfonamides as Carbonic Anhydrase Inhibitors: Synthesis, Biological and In Silico Studies.

作者信息

Angeli Andrea, Kartsev Victor, Petrou Anthi, Lichitsky Boris, Komogortsev Andrey, Pinteala Mariana, Geronikaki Athina, Supuran Claudiu T

机构信息

Sezione di Scienze Farmaceutiche, NeuroFarba Department, Universita degli Studi di Firenze, Via Ugo Schiff 6, 50019 Sesto Fiorentino, Italy.

Centre of Advanced Research in Bionanoconjugates and Biopolymers, Petru Poni Institute of Macromolecular Chemistry, Aleea Grigore Ghica-Voda, no. 41A, 700487 Iasi, Romania.

出版信息

Pharmaceuticals (Basel). 2022 Mar 7;15(3):316. doi: 10.3390/ph15030316.

DOI:10.3390/ph15030316
PMID:35337114
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8955975/
Abstract

Carbonic anhydrases (CAs, EC 4.2.1.1) catalyze the essential reaction of CO hydration in all living organisms, being actively involved in the regulation of a plethora of patho-/physiological conditions. A series of chromene-based sulfonamides were synthesized and tested as possible CA inhibitors. On the other hand, in microorganisms, the β- and γ- classes are expressed in addition to the α- class, showing substantial structural differences to the human isoforms. In this scenario, not only human but also bacterial CAs are of particular interest as new antibacterial agents with an alternative mechanism of action for fighting the emerging problem of extensive drug resistance afflicting most countries worldwide. Pyrazolo[4,3-c]pyridine sulfonamides were synthesized using methods of organic chemistry. Their inhibitory activity, assessed against the cytosolic human isoforms hCA I and hCA II, the transmembrane hCA IX and XII, and β- and γ-CAs from three different bacterial strains, was evaluated by a stopped-flow CO hydrase assay. Several of the investigated derivatives showed interesting inhibition activity towards the cytosolic associate isoforms hCA I and hCA II, as well as the 3β- and 3γ-CAs. Furthermore, computational procedures were used to investigate the binding mode of this class of compounds within the active site of hCA IX. Four compounds (, , and ) were more potent than AAZ against hCA I. Furthermore, compound also showed better activity than AAZ against the hCA II isoform. Moreover, ten compounds out of eleven appeared to be very potent against the γ-CA from with a Ki much lower than that of the reference drug. Most of the compounds showed better activity than AAZ against hCA I as well as the γ-CA from and the β-CA from Compounds and showed a good selectivity index against hCA I and hCA XII, while was selective against all 3β-CA isoforms from , , and and all 3γ-CA isoforms from , and

摘要

碳酸酐酶(CAs,EC 4.2.1.1)催化所有生物体内CO₂水合的关键反应,积极参与多种病理/生理状况的调节。合成了一系列基于色烯的磺酰胺并作为可能的CA抑制剂进行测试。另一方面,在微生物中,除了α类之外还表达β类和γ类,它们与人类异构体在结构上有很大差异。在这种情况下,人类和细菌的CAs作为新型抗菌剂都特别受关注,它们具有对抗全球大多数国家出现的广泛耐药性这一新兴问题的替代作用机制。使用有机化学方法合成了吡唑并[4,3-c]吡啶磺酰胺。通过停流CO₂水合酶测定法评估了它们对胞质人类异构体hCA I和hCA II、跨膜hCA IX和XII以及来自三种不同细菌菌株的β-和γ-CAs的抑制活性。几种研究的衍生物对胞质相关异构体hCA I和hCA II以及3β-和3γ-CAs表现出有趣的抑制活性。此外,使用计算程序研究了这类化合物在hCA IX活性位点内的结合模式。四种化合物(、、和)对hCA I的活性比AAZ更强。此外,化合物对hCA II异构体的活性也比AAZ更好。此外,十一种化合物中有十种对来自的γ-CA似乎非常有效,其Ki远低于参考药物。大多数化合物对hCA I以及来自的γ-CA和来自的β-CA的活性比AAZ更好。化合物和对hCA I和hCA XII表现出良好的选择性指数,而对来自、和的所有3β-CA异构体以及来自、和的所有3γ-CA异构体具有选择性

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f464/8955975/ca572a41b548/pharmaceuticals-15-00316-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f464/8955975/d16ca1c8672f/pharmaceuticals-15-00316-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f464/8955975/74eef67876f5/pharmaceuticals-15-00316-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f464/8955975/49d8f2df92b9/pharmaceuticals-15-00316-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f464/8955975/498b2bf54a61/pharmaceuticals-15-00316-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f464/8955975/d0381e506c84/pharmaceuticals-15-00316-sch002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f464/8955975/b035dea10777/pharmaceuticals-15-00316-sch003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f464/8955975/05548f364b38/pharmaceuticals-15-00316-sch004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f464/8955975/7d85f2ab6512/pharmaceuticals-15-00316-sch005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f464/8955975/d0e608a61e4a/pharmaceuticals-15-00316-sch006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f464/8955975/31d0ad1aad08/pharmaceuticals-15-00316-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f464/8955975/372e070f18f4/pharmaceuticals-15-00316-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f464/8955975/724dc6cf6be2/pharmaceuticals-15-00316-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f464/8955975/b54abb3b0459/pharmaceuticals-15-00316-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f464/8955975/112f02123712/pharmaceuticals-15-00316-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f464/8955975/ca572a41b548/pharmaceuticals-15-00316-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f464/8955975/d16ca1c8672f/pharmaceuticals-15-00316-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f464/8955975/74eef67876f5/pharmaceuticals-15-00316-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f464/8955975/49d8f2df92b9/pharmaceuticals-15-00316-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f464/8955975/498b2bf54a61/pharmaceuticals-15-00316-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f464/8955975/d0381e506c84/pharmaceuticals-15-00316-sch002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f464/8955975/b035dea10777/pharmaceuticals-15-00316-sch003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f464/8955975/05548f364b38/pharmaceuticals-15-00316-sch004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f464/8955975/7d85f2ab6512/pharmaceuticals-15-00316-sch005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f464/8955975/d0e608a61e4a/pharmaceuticals-15-00316-sch006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f464/8955975/31d0ad1aad08/pharmaceuticals-15-00316-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f464/8955975/372e070f18f4/pharmaceuticals-15-00316-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f464/8955975/724dc6cf6be2/pharmaceuticals-15-00316-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f464/8955975/b54abb3b0459/pharmaceuticals-15-00316-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f464/8955975/112f02123712/pharmaceuticals-15-00316-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f464/8955975/ca572a41b548/pharmaceuticals-15-00316-g009.jpg

相似文献

1
Pyrazolo[4,3-c]pyridine Sulfonamides as Carbonic Anhydrase Inhibitors: Synthesis, Biological and In Silico Studies.吡唑并[4,3-c]吡啶磺酰胺类碳酸酐酶抑制剂:合成、生物学及计算机模拟研究
Pharmaceuticals (Basel). 2022 Mar 7;15(3):316. doi: 10.3390/ph15030316.
2
Synthesis, Biological and In Silico Studies of Griseofulvin and Usnic Acid Sulfonamide Derivatives as Fungal, Bacterial and Human Carbonic Anhydrase Inhibitors.灰黄霉素和地衣酸磺酰胺衍生物的合成、生物和计算机研究作为真菌、细菌和人碳酸酐酶抑制剂。
Int J Mol Sci. 2023 Feb 1;24(3):2802. doi: 10.3390/ijms24032802.
3
Chromene-Containing Aromatic Sulfonamides with Carbonic Anhydrase Inhibitory Properties.含色烯的芳香族磺酰胺类化合物具有碳酸酐酶抑制特性。
Int J Mol Sci. 2021 May 11;22(10):5082. doi: 10.3390/ijms22105082.
4
Inhibition of carbonic anhydrase isoforms I, II, IX and XII with secondary sulfonamides incorporating benzothiazole scaffolds.含苯并噻唑骨架的仲磺酰胺对碳酸酐酶同工酶I、II、IX和XII的抑制作用。
J Enzyme Inhib Med Chem. 2016 Dec;31(6):1306-11. doi: 10.3109/14756366.2015.1128427. Epub 2016 Jan 8.
5
Novel 2-(hydrazinocarbonyl)-3-phenyl-1H-indole-5-sulfonamide based thiosemicarbazides as potent and selective inhibitors of tumor-associated human carbonic anhydrase IX and XII: Synthesis, cytotoxicity, and molecular modelling studies.新型 2-(肼羰基)-3-苯基-1H-吲哚-5-磺酰胺基硫代脒作为有效的肿瘤相关人碳酸酐酶 IX 和 XII 的抑制剂:合成、细胞毒性和分子模拟研究。
Bioorg Chem. 2024 Mar;144:107096. doi: 10.1016/j.bioorg.2024.107096. Epub 2024 Jan 23.
6
Extending the Inhibition Profiles of Coumarin-Based Compounds Against Human Carbonic Anhydrases: Synthesis, Biological, and In Silico Evaluation.扩展香豆素类化合物对人碳酸酐酶抑制谱的研究:合成、生物学及计算机模拟评价。
Molecules. 2019 Oct 4;24(19):3580. doi: 10.3390/molecules24193580.
7
Discovery of novel benzenesulfonamides incorporating 1,2,3-triazole scaffold as carbonic anhydrase I, II, IX, and XII inhibitors.发现新型苯磺酰胺类化合物,其中包含 1,2,3-三唑骨架,作为碳酸酐酶 I、II、IX 和 XII 的抑制剂。
Int J Biol Macromol. 2023 Jun 1;239:124232. doi: 10.1016/j.ijbiomac.2023.124232. Epub 2023 Mar 30.
8
S-substituted 2-mercaptoquinazolin-4(3H)-one and 4-ethylbenzensulfonamides act as potent and selective human carbonic anhydrase IX and XII inhibitors.S-取代的 2-巯基喹唑啉-4(3H)-酮和 4-乙基苯磺酰胺类化合物可作为强效和选择性的人碳酸酐酶 IX 和 XII 抑制剂。
J Enzyme Inhib Med Chem. 2020 Dec;35(1):733-743. doi: 10.1080/14756366.2020.1742117.
9
Carbonic anhydrase inhibitors. Synthesis, and molecular structure of novel series N-substituted N'-(2-arylmethylthio-4-chloro-5-methylbenzenesulfonyl)guanidines and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII.碳酸酐酶抑制剂。新型 N-取代的 N'-(2-芳甲基硫代-4-氯-5-甲基苯磺酰)胍的合成及分子结构及其对人胞质同工酶 I 和 II 以及跨膜肿瘤相关同工酶 IX 和 XII 的抑制作用。
Eur J Med Chem. 2014 Jan;71:135-47. doi: 10.1016/j.ejmech.2013.10.081. Epub 2013 Nov 10.
10
Synthesis and selective inhibitory effects of some 2-oxindole benzenesulfonamide conjugates on human carbonic anhydrase isoforms CA I, CA II, CA IX and CAXII.一些 2-氧代吲哚苯磺酰胺化合物的合成及对人碳酸酐酶同工酶 CA I、CA II、CA IX 和 CA XII 的选择性抑制作用。
Bioorg Chem. 2020 Jan;95:103514. doi: 10.1016/j.bioorg.2019.103514. Epub 2019 Dec 23.

引用本文的文献

1
Facile synthesis of aminobiphenyl sulfonamides via Chan-Lam coupling and their biological evaluation as potent carbonic anhydrase inhibitors.通过Chan-Lam偶联轻松合成氨基联苯磺酰胺及其作为强效碳酸酐酶抑制剂的生物学评价。
Sci Rep. 2025 Jul 15;15(1):25661. doi: 10.1038/s41598-025-10048-4.
2
Novel Inhibitors for MDM2-MDM4 E3 Ligase Potently Induce p53-Indepedent Apoptosis in Drug-Resistant Leukemic Cells.MDM2-MDM4 E3连接酶的新型抑制剂可有效诱导耐药白血病细胞发生不依赖p53的凋亡。
Molecules. 2025 Jan 5;30(1):186. doi: 10.3390/molecules30010186.
3
Novel 3-Sulfonamide Dual-Tail Pyrrol-2-one Bridged Molecules as Potent Human Carbonic Anhydrase Isoform Inhibitors: Design, Synthesis, Molecular Modeling Investigation, and Anticancer Activity in MeWo, SK-BR-3, and MG-63 Cell Lines.

本文引用的文献

1
Folic acid-sulfonamide conjugates as antibacterial agents: design, synthesis and molecular docking studies.作为抗菌剂的叶酸-磺胺共轭物:设计、合成及分子对接研究
RSC Adv. 2020 Nov 25;10(70):42983-42992. doi: 10.1039/d0ra09051d. eCollection 2020 Nov 23.
2
Aromatic Sulfonamides including a Sulfonic Acid Tail: New Membrane Impermeant Carbonic Anhydrase Inhibitors for Targeting Selectively the Cancer-Associated Isoforms.含磺酸基的芳基磺酰胺类化合物:新型膜不可渗透碳酸酐酶抑制剂,可选择性靶向与癌症相关的同工酶。
Int J Mol Sci. 2021 Dec 31;23(1):461. doi: 10.3390/ijms23010461.
3
Investigations on Anticancer and Antimalarial Activities of Indole-Sulfonamide Derivatives and Studies.
新型3-磺酰胺双尾吡咯-2-酮桥连分子作为有效的人碳酸酐酶同工酶抑制剂:设计、合成、分子模拟研究及在MeWo、SK-BR-3和MG-63细胞系中的抗癌活性
J Med Chem. 2025 Jan 23;68(2):1863-1882. doi: 10.1021/acs.jmedchem.4c02586. Epub 2025 Jan 10.
4
In silico study, synthesis, and antineoplastic evaluation of thiazole-based sulfonamide derivatives and their silver complexes with expected carbonic anhydrase inhibitory activity.基于噻唑的磺酰胺衍生物及其银配合物的计算机研究、合成及抗肿瘤活性评价。
J Med Life. 2023 Dec;16(12):1857-1863. doi: 10.25122/jml-2023-0180.
5
Synthetic Approaches to Novel Human Carbonic Anhydrase Isoform Inhibitors Based on Pyrrol-2-one Moiety.基于吡咯-2-酮部分的新型人碳酸酐酶同工酶抑制剂的合成方法。
J Med Chem. 2024 Feb 22;67(4):3018-3038. doi: 10.1021/acs.jmedchem.3c02190. Epub 2024 Feb 1.
6
Antimicrobial Potency and β-Carbonic Anhydrase Inhibition Efficacy of Phenazone-Based Molecules.基于苯佐那酯分子的抗菌效力和β-碳酸酐酶抑制效果。
Molecules. 2023 Nov 8;28(22):7491. doi: 10.3390/molecules28227491.
7
Synthesis, Biological and In Silico Studies of Griseofulvin and Usnic Acid Sulfonamide Derivatives as Fungal, Bacterial and Human Carbonic Anhydrase Inhibitors.灰黄霉素和地衣酸磺酰胺衍生物的合成、生物和计算机研究作为真菌、细菌和人碳酸酐酶抑制剂。
Int J Mol Sci. 2023 Feb 1;24(3):2802. doi: 10.3390/ijms24032802.
吲哚 - 磺酰胺衍生物的抗癌和抗疟活性研究及相关研究
ACS Omega. 2021 Nov 18;6(47):31854-31868. doi: 10.1021/acsomega.1c04552. eCollection 2021 Nov 30.
4
Carbonic Anhydrase Inhibition with Sulfonamides Incorporating Pyrazole- and Pyridazinecarboxamide Moieties Provides Examples of Isoform-Selective Inhibitors.含吡唑和哒嗪甲酰胺部分的磺胺类碳酸酐酶抑制剂为同工酶选择性抑制剂提供了范例。
Molecules. 2021 Nov 20;26(22):7023. doi: 10.3390/molecules26227023.
5
Recent Advances in the Development of Pyrazolopyridines as Anticancer Agents.吡唑并吡啶类化合物作为抗癌药物开发的最新进展
Anticancer Agents Med Chem. 2022;22(9):1643-1657. doi: 10.2174/1871520621666210901102832.
6
New Sulfanilamide Derivatives Incorporating Heterocyclic Carboxamide Moieties as Carbonic Anhydrase Inhibitors.含有杂环甲酰胺部分作为碳酸酐酶抑制剂的新型磺胺衍生物。
Pharmaceuticals (Basel). 2021 Aug 23;14(8):828. doi: 10.3390/ph14080828.
7
Synthesis of Antimicrobial Benzimidazole-Pyrazole Compounds and Their Biological Activities.抗菌苯并咪唑 - 吡唑化合物的合成及其生物活性
Antibiotics (Basel). 2021 Aug 19;10(8):1002. doi: 10.3390/antibiotics10081002.
8
Chromene-Containing Aromatic Sulfonamides with Carbonic Anhydrase Inhibitory Properties.含色烯的芳香族磺酰胺类化合物具有碳酸酐酶抑制特性。
Int J Mol Sci. 2021 May 11;22(10):5082. doi: 10.3390/ijms22105082.
9
Emerging role of carbonic anhydrase inhibitors.碳酸酐酶抑制剂的新作用
Clin Sci (Lond). 2021 May 28;135(10):1233-1249. doi: 10.1042/CS20210040.
10
Recent Progress in Anticancer Agents Incorporating Pyrazole Scaffold.含吡唑骨架抗癌药物的研究进展
Mini Rev Med Chem. 2022;22(1):115-163. doi: 10.2174/1389557521666210325115218.